6 June 2017
Chinese government confirms regulatory approval for iTrack™
Chinese government confirms regulatory approval for iTrack™ until 23 May 2022 – the only MIGS device to treat glaucoma approved in this market
Adelaide, Australia, 6 June 2017– Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical devices for the diagnosis and treatment of eye disease, today announced an extension of regulatory approval in China for its minimally invasive glaucoma surgery (MIGS) device, Ellex iTrack™.
On 2 June 2017, Ellex received advice from the Chinese government that the Ellex iTrack™ device’s approval for sale in China has been extended until 23 May 2022. Ellex iTrack™ is the only MIGS device approved for sale in China.
China is a key market segment for Ellex iTrack™ and the Company is working with its distributor to train doctors in the iTrack™ surgery technique and build sales in the country.
Ellex designs, develops, manufactures and sells innovative products that help eye surgeons around the world to effectively and efficiently treat eye disease. Ellex is a world leader in this field. Headquartered in Adelaide, Australia, Ellex has ophthalmic lasers and devices that treat glaucoma, retinal disease primarily caused by diabetes, secondary cataract and vitreous opacities, as well as age-related macular degeneration. Manufacturing is carried out in Adelaide, Australia and Fremont, California. Sales and service directly to eye surgeons is conducted via subsidiary offices in Minneapolis, Lyon, Berlin and Tokyo. A network of more than 50 distribution partners around the world services other markets.
For additional information about Ellex and its products, please visit www.ellex.com
For further information on Ellex please contact: